Skip to main content
Journal cover image

A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm.

Publication ,  Journal Article
Fezza, J; Burns, J; Woodward, J; Truong, D; Hedges, T; Verma, A
Published in: J Neurol Sci
August 15, 2016

To characterize satisfaction with current standard-of-care botulinum neurotoxin type A (BoNT/A) treatment for blepharospasm, we performed a cross-sectional, structured survey in subjects with blepharospasm who had received ≥2 BoNT/A cycles. Subjects were interviewed immediately before re-injection to evaluate treatment satisfaction, time course of treatment effects, preferred injection intervals, Jankovic Rating Scale (JRS), and Blepharospasm Disability Index (BSDI). Subjects' (n=114) last treatment was onabotulinumtoxinA (n=78), incobotulinumtoxinA (n=35), or abobotulinumtoxinA (n=1). The most frequent injection interval was 12weeks (46.5% subjects); 30.7% had an interval >12weeks. The main rationale for interval choice was "to maintain treatment efficacy" (44.7%). However, 36.6% reported that treatment effects usually declined within 8weeks; 69.6% within 10weeks. JRS and BSDI scores indicated re-emergence of symptoms before re-injection, with 70.2% and 73.7% of subjects reporting difficulties to drive and read, respectively. Overall, treatment satisfaction was high, but declined at the end of the cycle. Many subjects (52.3%) would prefer an injection interval of <12weeks; 30.6% of <10weeks. In conclusion, the survey results indicate that blepharospasm symptoms, such as difficulties to drive and read, re-emerge at the end of a BoNT treatment cycle and that flexible, individualized treatment intervals may improve treatment satisfaction and outcomes.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Neurol Sci

DOI

EISSN

1878-5883

Publication Date

August 15, 2016

Volume

367

Start / End Page

56 / 62

Location

Netherlands

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Severity of Illness Index
  • Reading
  • Patient Satisfaction
  • Neuromuscular Agents
  • Middle Aged
  • Male
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fezza, J., Burns, J., Woodward, J., Truong, D., Hedges, T., & Verma, A. (2016). A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm. J Neurol Sci, 367, 56–62. https://doi.org/10.1016/j.jns.2016.05.033
Fezza, John, John Burns, Julie Woodward, Daniel Truong, Thomas Hedges, and Amit Verma. “A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm.J Neurol Sci 367 (August 15, 2016): 56–62. https://doi.org/10.1016/j.jns.2016.05.033.
Fezza J, Burns J, Woodward J, Truong D, Hedges T, Verma A. A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm. J Neurol Sci. 2016 Aug 15;367:56–62.
Fezza, John, et al. “A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm.J Neurol Sci, vol. 367, Aug. 2016, pp. 56–62. Pubmed, doi:10.1016/j.jns.2016.05.033.
Fezza J, Burns J, Woodward J, Truong D, Hedges T, Verma A. A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm. J Neurol Sci. 2016 Aug 15;367:56–62.
Journal cover image

Published In

J Neurol Sci

DOI

EISSN

1878-5883

Publication Date

August 15, 2016

Volume

367

Start / End Page

56 / 62

Location

Netherlands

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Severity of Illness Index
  • Reading
  • Patient Satisfaction
  • Neuromuscular Agents
  • Middle Aged
  • Male
  • Humans
  • Female